The news followed an investigation by POLITICO's E&E News into climate-friendly inhalers and how drug giants are developing ...

GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly half (49%) of the group’s ...

Americans with asthma and 16 million Americans with COPD need inhalers to breathe. Vermont Business Magazine Sen. Bernie Sanders (I-Vermont), Chairman of the Senate Com ...

Massachusetts families are still struggling to find alternatives almost a year after GlaxoSmithKline canceled a widely ...

Nov 19 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat patients with a so-called ...

LONDON — A blood cancer treatment from GSK helped patients live longer in a pivotal trial, a significant finding as the once-withdrawn drug mounts a comeback. In the study, a treatment ...

Companies like AstraZeneca and GSK, which have high-revenue-generating inhalers for asthma and chronic obstructive pulmonary disorder (COPD) in their portfolios, have each committed to becoming ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to launch the first treatment for the relentless itching experienced by some ...

Efforts to supplant pressurised metered-dose inhalers (pMDIs) with DPIs, most recently by the European Network on Climate and Health Education (ENCHE), have gained steam in recent years. Companies ...